Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
SIEMENS AKTIENGESELLSCHAFT	WERNER-VON-SIEMENS-STRASSE 1 80333 MÜNCHEN 80333

International Classification(s)

• H02G:INSTALLATION OF ELECTRIC CABLES OR LINES, OR OF CO....

• 2016 Application Filing Year
• H02G Class
• 946 Applications Filed
• 743 Patents Issued To-Date
• 78.55 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
DEHLER, ANDREAS	MUENCHEN, DE	1	0
# of filed Patents : 1 Total Citations : 0
EBNER, ANDREAS	NUERNBERG, DE	10	90
# of filed Patents : 10 Total Citations : 90
IMAMOVIC, DENIS	NUERNBERG, DE	3	11
# of filed Patents : 3 Total Citations : 11
MAGIER, TOMASZ	EGGOLSHEIM, DE	3	5
# of filed Patents : 3 Total Citations : 5
SCHEDL, STEFAN	AMMERNDORF, DE	1	0
# of filed Patents : 1 Total Citations : 0

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 0 Citation Count
• H02G Class

• 0 % this patent is cited more than
• 7 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
7.5 Year Payment	$3600.00	$1800.00	$900.00	Aug 1, 2025
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Aug 1, 2029

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 7.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2012/0128,649

MODIFIED NON-CYTOTOXIC PROTEASES

---

Abstract

---

The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognised and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.